 |
John Gribben, M.D., DSc
Barts Cancer Center of Excellence/
The London School of Medicine (United Kingdom) |
John Gribben is a Professor of Experimental Cancer Medicine, Director of the
Experimental Cancer Medicine Centre and Director of Stem Cell Transplantation
at St. Bartholomew's Hospital, Queen Mary's School of Medicine, University of
London.
After obtaining his medical degree, he spent 5 years as a Research Fellow in
Haematology at University College London, where he was a Leukaemia Research Fund
Fellow and recipient of a Welcome Trust Fellowship Award. In 1989, he received
a Fogarty International Fellowship to continue post-doctoral training at the Dana-Farber
Cancer Institute, Harvard Medical School. In 1992, he was appointed to the Faculty
at Harvard Medical School, where he remained an Associate Professor of Medicine
and an Attending Physician at the Dana-Farber Cancer Institute and Brigham and
Women's Hospital, until moving to London in October 2004. He is also a founding
member of the CLL Research Consortium.
An internationally recognized translational cancer researcher, John Gribben
is an author of more than 200 manuscripts and book chapters. His primary research
interests include the immunotherapy of cancer (including stem-cell transplantation);
the identification of B-cell-tumour antigens; and the detection and treatment
of minimal residual disease in leukaemia and lymphoma. He is also an Associate
Editor of Blood.
|